Children’s Cancer Research Fund (CCRF) is a national nonprofit committed to finding safer, more effective therapies for kids battling cancer. Thanks to donors and partners around the country, we have contributed over $200 million to research, education and awareness, and quality-of-life programs for childhood cancer families. We believe kids deserve safer, less toxic treatments, and we’re committed to funding groundbreaking research and services that enhance healing and care.
In 2021, CCRF welcomes applications in the following grant categories:
- Emerging Scientist Awards – opening April 12, 2021
- Accelerating Impact for Hard to Treat Cancers – opening July 2021
- Survivorship – opening August 2021
All applications for CCRF awards must be submitted through ProposalCENTRAL. Each application is peer reviewed, and the Research Advisory Committee (RAC) will make funding recommendations to the CCRF Board of Directors.
Please email email@example.com with any questions about our award programs or the application process.
Emerging Scientist Award
This award is designed to develop the independent research of exceptional investigators still early in their careers. An Emerging Scientist Award is $100,000 for a one-year period.
The Emerging Scientist award supports basic, clinical, translational, or epidemiological research. Projects may include pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; and development of new research technology.
Applicants should have a post-graduate doctoral degree in a field of medical or scientific research specialty and hold a research or faculty appointment at an accredited university or comparable research institution. Applicants must be within the first seven (7) years of their initial independent full research or faculty appointment at the time the award begins.
Emerging Scientist Award applications will be accepted from April 12 through May 20, 2021 at Noon (Central time). Award recipients will be notified in early August for an October 1, 2021 project start date.
A full funding announcement and application instructions will be available in early April. View funding announcement here.
Please review the funding announcement and application instructions for complete details on how to apply for this award.
Accelerating Impact for Hard to Treat Cancers Award
This award supports basic, clinical, and population studies focused on hard-to-treat cancers where treatment success has remained out of reach. Projects may include pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. A Hard-to-Treat Award is $250,000 for a two-year period.
CCRF defines hard-to-treat cancer as 5-year survival less than 70% in an individual cancer (e.g. osteosarcoma, AML, DIPG), in a cancer with unfavorable behavior (e.g. relapse or metastasis), or in a molecular defined subtype (e.g. MLL rearranged leukemia, PAX3-FOXO1 rearranged RMS). Cancers with survival <70% in demographic groups defined by age, sex, or race/ethnicity may also qualify if a biologic hypothesis is being pursued.
Letters of Intent (LOIs) for this award will be accepted from June 28 through July 15, 2021 at Noon (Central time). LOIs will be peer reviewed to determine which applicants will be invited to submit a full application. Full applications are due on September 15, 2021 at Noon (Central time).
We invite applications that focus on improving the quality and quantity of life for childhood, adolescent and young adult cancer survivors. Our goal is to support development of interventions that prevent, minimize and address the late effects of cancer therapies. A specific focus of this FOA is on applications that propose to translate basic research into interventions, regardless of whether these take place during active therapy or later. Observational studies are welcome but are a lower priority, with the exception of those describing late effects (or early signs of late effects) among children receiving novel agents or therapies.
Letters of Intent (LOIs) for this award will be accepted from August 30 to September 14, 2021 at Noon (Central time). LOIs will be peer reviewed to determine which applicants will be invited to submit a full application. Full applications are due on November 11, 2021 at Noon (Central time).